Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Autozone Inc (AZO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Autozone Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.7 (market cap $29.60B), while Autozone Inc trades at $3,045 (market cap $49.67B). The key difference: Autozone Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ALNY | AZO | |
|---|---|---|
Market Cap | $29.60B | $49.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $4.35K |
52-Week Low | $205.48 | $2.92K |
Enterprise Value | $27.56B | $62.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
AutoZone (AZO) trades at $3,050.43, down 0.57% on the day, with a neutral technical signal and bullish moving averages. The company reported Q1 2026 EPS of $38.07, beating expectations, but revenue growth has slowed with a net income margin of 12.4% in 2025. Analyst consensus is strongly bullish with a $3,730 price target, though recent insider selling and institutional trimming pose sentiment headwinds.
The outlook remains positive given earnings beats and international expansion, but risks include competitive pressures, margin compression, and macroeconomic sensitivity. Upside is supported by a high GF Score of 84 and DCF valuation above $3,800, yet investors should monitor execution on Q2 2026 earnings and capex efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
